Company

Company

Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Integra Therapeutics

Main focus: Gene editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases: Undisclosed

Genome editing tool: Undisclosed

Funding stage: Private

Location: Barcelona, Catalonia, Spain

Website: https://integra-tx.com/

Integra Therapeutics is a start-up company focused on next-generation gene writing. The technology is based on the CRISPR system, which has been merged with transposase and integrase proteins that have a great capacity for gene transfer. Thus, the system does not depend on viral vectors for transporting the gene-editing components into the cell. The company yet has to disclose the specifics of the technology, as well as its lead therapeutic candidates.

Integra Therapeutics

Your Latest CMN News

CMN Weekly (26 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

SNIPR Biome Receives CARB-X Funding to Test...

SNIPR Biome announced today that it has secured funding from CARB-X to further advance SNIPR001 into clinical trials in haematological cancer...

CMN Weekly (19 April 2024) - Your Weekly CRISPR...

Some of the best links we picked up around the internet

A Secondary Checkpoint Refines CRISPR Precision

New findings highlight a secondary conformational checkpoint in CRISPR-Cas9 that significantly enhances its accuracy in gene editing.

Cancer's Weak Point Is Its Metabolism, CRISPR...

American researchers have developed a novel CRISPR-based platform to identify and characterise essential nutrient transporters that support cancer...

Next-Generation CRISPR Screening Libraries Without...

Sponsored content

Founded in 2018, Vivlion is a spin-out of Goethe University Frankfurt. Its mission is to provide innovative gene-editing reagents and screening...

Company: Integra Therapeutics

Search CRISPR Medicine